Cargando…
Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
Autores principales: | Dimosiari, Athina, Patoulias, Dimitrios, Pantazopoulos, Ioannis, Zakynthinos, Epaminondas, Makris, Demosthenes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666376/ https://www.ncbi.nlm.nih.gov/pubmed/36462963 http://dx.doi.org/10.1016/j.ejim.2022.11.014 |
Ejemplares similares
-
Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
por: Dimosiari, Athina, et al.
Publicado: (2022) -
Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022) -
Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022) -
Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021) -
COVID-19 Mortality Differences: Patient-related Data and Intensive Care Unit Load Are Prerequisites
por: Tsolaki, Vasiliki, et al.
Publicado: (2022)